Werewolf Therapeutics’ (HOWL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock opened at $1.78 on Tuesday. The firm has a market capitalization of $79.32 million, a PE ratio of -1.16 and a beta of 0.41. The company has a 50 day moving average price of $2.23 and a 200-day moving average price of $2.76. Werewolf Therapeutics has a 52 week low of $1.58 and a 52 week high of $8.19. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.

Institutional Trading of Werewolf Therapeutics

Several large investors have recently modified their holdings of the company. Walleye Capital LLC boosted its holdings in shares of Werewolf Therapeutics by 10.7% in the third quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after buying an additional 10,528 shares during the last quarter. American Century Companies Inc. lifted its position in Werewolf Therapeutics by 50.7% during the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after purchasing an additional 12,656 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Werewolf Therapeutics in the third quarter worth about $29,000. Point72 DIFC Ltd bought a new position in shares of Werewolf Therapeutics in the second quarter worth about $34,000. Finally, XTX Topco Ltd purchased a new position in shares of Werewolf Therapeutics during the 3rd quarter valued at about $45,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.